G

Global Blood Therapeutics Inc
F:G5B

Watchlist Manager
Global Blood Therapeutics Inc
F:G5B
Watchlist
Price: 68.4 EUR -1.27%
Market Cap: 4.6B EUR

Operating Margin
Global Blood Therapeutics Inc

-127.4%
Current
-1 355%
Average
-4.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-127.4%
=
Operating Profit
-299.2m
/
Revenue
234.9m

Operating Margin Across Competitors

No Stocks Found

Global Blood Therapeutics Inc
Glance View

Market Cap
4.6B EUR
Industry
Biotechnology

Global Blood Therapeutics Inc., often abbreviated as GBT, was born out of a specialized mission: to address the overlooked and pervasive medical challenges associated with sickle cell disease (SCD). Founded in the bustling biotech hub of South San Francisco in 2011, GBT has positioned itself at the forefront of developing novel therapeutics for blood disorders. The company harnessed cutting-edge research to create its flagship product, Oxbryta (voxelotor), a groundbreaking oral therapy that targets the root cause of SCD by increasing hemoglobin's affinity for oxygen. Unlike the traditional approach of merely managing symptoms, Oxbryta works by directly ameliorating the hemoglobin polymerization that leads to sickling of red blood cells, offering patients hope for improved quality of life. GBT's revenue model is deeply intertwined with the biopharmaceutical landscape, generating income primarily through the commercialization of its innovative therapies. With Oxbryta leading its product offerings, the company has accessed a growing market of SCD patients seeking effective treatment options. By navigating the intricate web of healthcare providers and leveraging its relationships with payers and professionals, GBT has strategically anchored its operations in markets with significant unmet medical needs. The company also allocated resources toward research and development to fuel its pipeline, hoping to expand its portfolio beyond SCD. This comprehensive strategy not only underscores GBT’s commitment to transforming patient care but also strengthens its competitive position in the fast-evolving pharmaceutical industry.

G5B Intrinsic Value
Not Available
G
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-127.4%
=
Operating Profit
-299.2m
/
Revenue
234.9m
What is the Operating Margin of Global Blood Therapeutics Inc?

Based on Global Blood Therapeutics Inc's most recent financial statements, the company has Operating Margin of -127.4%.

Back to Top